electroCore, Inc. (ECOR)

NASDAQ: ECOR · IEX Real-Time Price · USD
5.88
+0.26 (4.63%)
Dec 1, 2023, 4:30 PM EST - Market closed
4.63%
Market Cap 35.29M
Revenue (ttm) 13.40M
Net Income (ttm) -20.59M
Shares Out 6.00M
EPS (ttm) -4.19
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 6,514
Open 5.59
Previous Close 5.62
Day's Range 5.59 - 5.95
52-Week Range 3.10 - 7.50
Beta 1.00
Analysts Strong Buy
Price Target 14.88 (+153.06%)
Earnings Date Nov 8, 2023

About ECOR

electroCore, Inc., a commercial-stage bioelectronic medicine and wellness company, engages in the development and commercialization of a range of non-invasive vagus nerve stimulation (nVNS) therapies. The company is developing gammaCore, a prescription-only nVNS therapy for the acute treatment of pain associated with migraine and episodic cluster headache in adults; Truvaga for the support of general health and wellbeing; and TAC-STIM, a form of nVNS for human performance. Its lead product is gammaCore Sapphire, a rechargeable and reloadable ha... [Read more]

Industry Medical Devices
Sector Healthcare
IPO Date Jun 22, 2018
Employees 62
Stock Exchange NASDAQ
Ticker Symbol ECOR
Full Company Profile

Financial Performance

In 2022, electroCore's revenue was $8.59 million, an increase of 57.62% compared to the previous year's $5.45 million. Losses were -$22.16 million, 28.7% more than in 2021.

Financial Statements

Analyst Forecast

According to 2 analysts, the average rating for ECOR stock is "Strong Buy." The 12-month stock price forecast is $14.88, which is an increase of 153.06% from the latest price.

Price Target
$14.88
(153.06% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Dr. Peter Staats to Host Analyst Day on the Science Behind gammaCore™ Non-Invasive Vagus Nerve Stimulation (nVNS) on Tuesday, November 21, 2023

ROCKAWAY, N.J., Nov. 15, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that the Company's Chief Medical Off...

18 days ago - GlobeNewsWire

electroCore Announces Third Quarter 2023 Financial Results

Record third quarter 2023 net sales of $4.5 million, an increase of approximately 128% over third quarter 2022 Company increases revenue guidance for full year 2023 to $15.0 million - $15.5 million  C...

25 days ago - GlobeNewsWire

electroCore to Participate in Canaccord Genuity's MedTech, Diagnostics and Digital Health & Services Forum

ROCKAWAY, N.J., Nov. 07, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that Company CEO, Dan Goldberger, is...

26 days ago - GlobeNewsWire

Data Highlighting Non-invasive Vagus Nerve Stimulation (nVNS) for Treatment of Symptoms of Gastroparesis Presented at 2023 American College of Gastroenterology Annual Meeting

Clinical Trial suggests nVNS can reduce the use of rescue medications for exacerbations of nausea due to Gastroparesis or Functional Dyspepsia Clinical Trial suggests nVNS can reduce the use of rescue...

5 weeks ago - GlobeNewsWire

electroCore Announces Two-Year Extension of gammaCore™ Device Listing in the NHS Supply Chain Catalogue

ROCKAWAY, N.J., Oct. 17, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial stage bioelectronic medicine and wellness company, announced today that gammaCore therapy will continue...

6 weeks ago - GlobeNewsWire

electroCore Expands Intellectual Property Portfolio for Non-Invasive Vagus Nerve Stimulation (nVNS) Technology

ROCKAWAY, N.J., Oct. 11, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the United States Patent and Tradema...

7 weeks ago - GlobeNewsWire

Data Highlighting Non-Invasive Vagus Nerve Stimulation (nVNS) for Treatment of Acute Neurological Injury Presented at 2023 World Stroke Congress

“VANQUISH” Clinical Trial (n=40) suggests safety and efficacy of nVNS for the Treatment of Headache Associated with Subarachnoid Hemorrhage (SAH)

7 weeks ago - GlobeNewsWire

electroCore to Announce Third Quarter Financial Results on Wednesday, November 8

ROCKAWAY, N.J., Oct. 09, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that it will report financial result...

7 weeks ago - GlobeNewsWire

electroCore to Participate in the Lytham Partners Fall 2023 Virtual Investor Conference

ROCKAWAY, N.J., Oct. 05, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that Company CEO, Dan Goldberger, wi...

2 months ago - GlobeNewsWire

gammaCore Non-Invasive Vagus Nerve Stimulation (nVNS) Improves Attention and Working Memory in Patients with Post Traumatic Stress Disorder (PTSD)

Two prospective, peer reviewed trials demonstrate the symptomatic benefit of gammaCore in patients with PTSD Two prospective, peer reviewed trials demonstrate the symptomatic benefit of gammaCore in p...

2 months ago - GlobeNewsWire

electroCore to Participate in the LD Micro Main Event XVI Conference

ROCKAWAY, N.J., Sept. 25, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that Company CEO, Dan Goldberger, w...

2 months ago - GlobeNewsWire

electroCore to Present at iAccess Alpha's – Top 10 Best Ideas from the Buyside Virtual Conference

ROCKAWAY, N.J., Sept. 21, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that Company CEO, Dan Goldberger, w...

2 months ago - GlobeNewsWire

electroCore to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

ROCKAWAY, N.J., Sept. 07, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that Company CEO, Dan Goldberger, w...

3 months ago - GlobeNewsWire

electroCore Announces Dismissal of All Litigation Related to Its 2018 Initial Public Offering

ROCKAWAY, N.J., Aug. 23, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic and wellness company, today announced that it has been completely vindicated in the...

3 months ago - GlobeNewsWire

electroCore Announces Second Quarter 2023 Financial Results

Record second quarter 2023 net sales of $3.6 million, an increase of approximately 65% over second quarter 2022 Company to host a conference call and webcast today, August 9, 2023 at 4:30 PM EDT ROCKA...

4 months ago - GlobeNewsWire

electroCore to Announce Second Quarter Financial Results on Wednesday, August 9

ROCKAWAY, N.J., Aug. 01, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that it will report financial result...

4 months ago - GlobeNewsWire

electroCore, Inc. Announces $8.145 Million Registered Direct Offering and Concurrent Private Placements Priced At Market Under Nasdaq Rules

ROCKAWAY, N.J., July 31, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR) (“electroCore” or the “Company”), a commercial-stage bioelectronic medicine and wellness company, today announced tha...

4 months ago - GlobeNewsWire

gammaCore (Non-Invasive Vagus Nerve Stimulation; nVNS) Improves Attention and Memory in Patients with Posttraumatic Stress Disorder (PTSD)

ROCKAWAY, N.J., July 25, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the publication of a peer reviewed m...

4 months ago - GlobeNewsWire

electroCore Expands Intellectual Patent Portfolio for nVNS Technology

ROCKAWAY, N.J., July 18, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the United States Patent and Tradema...

4 months ago - GlobeNewsWire

electroCore, Inc. Announces Distribution Agreement with Reliefband Technologies, LLC

ROCKAWAY, N.J., July 13, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that ReletexTM by Reliefband, the fi...

5 months ago - GlobeNewsWire

electroCore Provides Select Second Quarter 2023 Financial Guidance

Record revenue of approximately $3,550,000 for the three months ended June 30, 2023; 65% increase over second quarter of 2022 Record revenue of approximately $3,550,000 for the three months ended June...

5 months ago - GlobeNewsWire

TAC-STIM™ Non-Invasive Vagal Nerve Stimulation Selected for Inclusion in the Air Force Research Laboratories Real-Time Assessing and Augmenting Cognitive Performance in Extreme Environments Project

ROCKAWAY, N.J., June 27, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that its TAC-STIM non-invasive vagus...

5 months ago - GlobeNewsWire

electroCore to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC

ROCKAWAY, N.J., June 14, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that Company CEO, Dan Goldberger, wi...

6 months ago - GlobeNewsWire

electroCore Announces Poster to be Presented at the American Headache Society's 65th Annual Scientific Meeting

ROCKAWAY, N.J., June 13, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that “SUNCT/ SUNA with neurovascular...

6 months ago - GlobeNewsWire

electroCore, Inc. Announces Departure of JP Errico from the Board of Directors

ROCKAWAY, N.J., May 26, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the resignation of its Founder and fo...

6 months ago - GlobeNewsWire